22 Feb 2021
Helperby’s mission is to develop approved anti-infective drugs into cost-effective combinations with synergistic anti-microbial activity to treat WHO Critical Priority Infections. Such combinations markedly reduce future antimicrobial resistance (AMR),...
18 Jun 2020
Helperby Therapeutics aims to produce affordable, rapid and effective combination solutions to treat infectious disease. COVID-19 has drawn attention to how unprepared we are to find treatments quickly for pandemics....
17 Jun 2020
Helperby’s commercial model is to develop combinations of repurposed old drugs to fight common resistant bacterial infections. Currently, this combination model is universally utilised for the treatment of diseases...
19 Oct 2019
Combinations of old antimicrobials such as Helperby’s colistin and azidothymidine are a possible alternative to developing new chemical entities, because they cost one tenth of the price. A Global...
24 Sep 2019
The New England Journal of Medicine announces that Azidothymidine produces synergistic activity in combination with Colistin against antibiotic-resistant Enterobacteriaceae. Antimicrobial Agents Chemother. doi:10.1128/AAC.01630-18. The NEJM review entitled Colistin-Azidothymidine...
26 Mar 2019
Click here to read the full article featuring Professor Sir Anthony Coates & Helperby Therapeutics
27 Feb 2019
19 Feb 2019
The World Health Organization recognises antimicrobial resistance (AMR) as one of the most pressing global threats to medicine. Without effective antibiotics, much of the success of modern medicine,...
12 Nov 2018
Helperby has announced a collaboration with Dr. Pamela Yeh and her team at the Department of Ecology and Evolutionary Biology, University of California, Los Angeles (UCLA). Dr Yeh recently published...
15 Jun 2018
Helperby Therapeutics announces study results demonstrating promise of its unique combination antibiotic therapy - active against the WHO Critical Priority Carbapenem resistant bacterial pathogens The combination...
26 Apr 2018
P2195 Safety and pharmacokinetics of i.v. azidothymidine alone and combined with colistin being developed for the treatment of carbapenem - and colistin- resistant Enterobacteriaceae (phase-1-study) Azidothymidine (AZT) in...
25 Apr 2018
O0574 Azidothymidine is bactericidal against carbapenem-resistant Enterobacteriaceae and produces synergistic activity in combination with colistin against multidrug-resistant Enterobacteriaceae Bacterial infections remain the leading killer worldwide which is worsened by...
25 Apr 2018
The combination is azidothymidine (AZT), which is a new class antibacterial, and low dose colistin. The combination is active against all three WHO Critical Priority Carbapenem Resistant Pathogens. In addition,...
14 Feb 2018
Tens of thousands of patients in Britain are struck down by superbugs because antibiotics to protect them during surgery have failed, a global study says. One in five infections picked...
17 Nov 2017
The European Centre for Disease Prevention and Control (ECDC) released the latest annual data on antimicrobial resistance trends in 30 European Union (EU) and European Economic Area (EEA) countries today, in...
13 Nov 2017
Doctors increasingly rely on last resort antibiotics such as carbapenems and colistin, but as harmful bacteria continue to mutate, this final line of resistance will eventually fail. The World Health...
26 May 2016
Helperby’s antibiotic-resistance breakers are a powerful tool serving to prolong and boost antibiotic efficacy and should help counter the growing global crisis of antibiotic resistance....
9 Apr 2016
On March 9th 2016 Helperby Therapeutics held a pre-IND meeting with the FDA division of Anti-Infective products. The outcome is a road map for the clinical development of a drug product...